SCHEMBL5544639

SCHEMBL5544639

CCCCOc1ccc(CN[CH]c2ccccc2)cc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.51
LMNA P02545 1/20 0.46
FAAH O00519 4/20 0.45
CYP1A2 P05177 2/20 0.44
CYP2D6 P10635 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
CYP3A4 P08684 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
KDM4E B2RXH2 1/20 0.43
PDE4A P27815 1/20 0.43
HIF1A Q16665 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5544473 0.81 RAB9A (0.57) LTA4HSMN1; SMN2KDM4EHIF1AMEN1
SCHEMBL5535543 0.78 SMN1; SMN2 (0.51) LMNAFAAHCYP1A2CYP2D6SMN1; SMN2
SCHEMBL7385255 0.76 ADH1B (0.58) CYP3A4GAAMAPTHPGDKDM4E
SCHEMBL5542584 0.75 SMN1; SMN2 (0.49) LMNACYP1A2SMN1; SMN2CYP3A4MAPT
SCHEMBL7440968 0.75 LTA4H (0.63) LTA4HFAAHCYP1A2CYP2D6MAPT
SCHEMBL5741015 0.75 RELA (0.72) LTA4HLMNACYP1A2CYP2D6SMN1; SMN2
SCHEMBL1618632 0.75 RELA (0.72) LTA4HLMNACYP1A2CYP2D6SMN1; SMN2
SCHEMBL1331014 0.74 LTA4H (0.87) LTA4HLMNACYP1A2CYP2D6SMN1; SMN2
SCHEMBL36192 0.74 LTA4H (0.87) LTA4HLMNACYP1A2CYP2D6SMN1; SMN2
Benzene SCHEMBL28132981 0.74 LTA4H (0.87) LTA4HLMNACYP1A2CYP2D6SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 LTA4H 3452/4885LMNA 4152/4885FAAH 4363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.